A case of dramatic heart chambers reverse remodeling and disease regression in a patient with heart failure and end-stage renal failure treated with Sacubitril/Valsartan and SGLT2i: the importance of pushing the boundaries
Anno:
2023
Background: Heart failure (HF) therapy has been disrupted by the introduction of 2 new prognostic-relevant drugs: Sacubitril/Valsartan and SGLT2i. However, the amount of evidence for guideline-directed HF therapies in the context of chronic kidney disease (CKD) is relatively modest, especially in advanced stages (e.g., on haemodialysis). Aim of this report is…